Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers

Clinical trial NCT03195699 · COMPLETED

Trial details

NCT number: NCT03195699
Sponsor: Tvardi Therapeutics, Incorporated
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Breast Cancer Head and Neck Squamous Cell Carcinoma Non Small Cell Lung Cancer Hepatocellular Cancer Colorectal Cancer Gastric Adenocarcinoma Melanoma Advanced Cancer

Start date: 2017-11-15
Primary completion: 2024-06-24
Enrollment: 64

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.